AFF1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (0 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (0 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains ELL status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 2 are phase 1 (2 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 0 are open and 1 is closed. Of the trial that contains MYC status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].

UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains UGT1A1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [3].